Sort   by:  
 Page size 
UnknownSHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.
Not available
S-EPMC12200682 | biostudies-literature
UnknownSafety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women.
Not available
S-EPMC9727091 | biostudies-literature
UnknownDiscovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.
Not available
S-EPMC8080595 | biostudies-literature
UnknownEfficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.
Not available
S-EPMC11694305 | biostudies-literature
UnknownA multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma.
Not available
S-EPMC9732039 | biostudies-literature
UnknownDiscovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors.
Not available
S-EPMC7883375 | biostudies-literature
UnknownAntitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Not available
S-EPMC8753451 | biostudies-literature
UnknownDiscovery of Imidazoisoindole Derivatives as Highly Potent and Orally Active Indoleamine-2,3-dioxygenase Inhibitors.
Not available
S-EPMC6580535 | biostudies-literature
UnknownFirst-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Not available
S-EPMC10882294 | biostudies-literature
UnknownDiscovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.
Not available
S-EPMC5955975 | biostudies-literature
Sort   by:  
 Page size